Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer

NCT01964027 is registered in ClinicalTrials.gov with Anhui Medical University as lead sponsor.

NCT NCT01964027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01964027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer
Lead sponsor
Anhui Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2013
Completion date
December 31, 2014
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv gastric cancer with metastasis